Motilium-M

Domperidone maleate.

One film-coated tablet contains 12.72 mg domperidone maleate, equivalent to 10 mg domperidone.
Excipients/Inactive Ingredients: corn starch, lactose monohydrate, pregelatinized starch, microcrystalline cellulose, polyvidone (PVP K90), polysorbate 20, colloidal silicon dioxide, magnesium stearate, Hydroxy Propyl Methyl Cellulose (Hypromellose), propylene glycol.

Pharmacotherapeutic group: Propulsives. ATC code: A03FA03.
Pharmacology: Pharmacodynamics: Domperidone is a dopamine antagonist with anti-emetic properties. Domperidone does not readily cross the blood-brain barrier. In domperidone users, especially in adults, extrapyramidal side effects are very rare, but domperidone promotes the release of prolactin from the pituitary. Its anti-emetic effect may be due to a combination of peripheral (gastrokinetic) effects and antagonism of dopamine receptors in the chemoreceptor trigger zone, which lies outside the blood-brain barrier in the area postrema. Animal studies, together with the low concentrations found in the brain, indicate a predominantly peripheral effect of domperidone on dopamine receptors.
Studies in man have shown oral domperidone to increase lower esophageal pressure, improve antroduodenal motility and accelerate gastric emptying. There is no effect on gastric secretion.
Effect on QT/QTc Interval and Cardiac Electrophysiology: In accordance with ICH-E14 guidelines, a thorough QT study was performed in healthy subjects. This study included a placebo, active comparator and positive control and was conducted using recommended and supra-therapeutic doses (10 and 20 mg administered 4 times a day). This study found a maximal difference of QTc between domperidone and placebo in LS-means in the change from baseline of 3.4 msec for 20 mg domperidone administered 4 times a day on Day 4, and the 2-sided 90% CI (1.0 5.9 msec) did not exceed 10 msec. The QT prolongation observed in this study when domperidone was administered according to the recommended dosing regimen is not clinically relevant.
This lack of clinical relevance is corroborated by pharmacokinetics and QTc interval data from two older studies which involved a 5-day treatment of 20 mg and 40 mg domperidone administered 4 times a day. ECGs were recorded prior to the study, on Day 5 at 1 hour (approximately at t_max) after the morning dose, and 3 days later. In both studies, no difference between QTc after active treatment and placebo was observed. It was therefore concluded that domperidone administration of 80 and 160 mg daily doses had no clinically significant effect on QTc in healthy subjects.
Pharmacokinetics: Absorption: In fasting subjects, domperidone is rapidly absorbed after oral administration, with peak plasma concentrations occurring at approximately 60 minutes after dosing. The key pharmacokinetic parameters after a single or multiple doses (administered 4 times a day) of 10 mg domperidone base tablets to healthy subjects are presented in the table as follows. The C_max and AUC values of domperidone increased proportionally with dose in the 10 mg to 20 mg dose range. (See Table 1.)

Click on icon to see table/diagram/image

The low absolute bioavailability of oral domperidone (approximately 15%) is due to an extensive first-pass metabolism in the gut wall and liver. Although domperidone's bioavailability is enhanced in normal subjects when taken after a meal, patients with gastro-intestinal complaints should take domperidone 15-30 minutes before a meal. Reduced gastric acidity impairs the absorption of domperidone base. Oral bioavailability of domperidone base is decreased by prior concomitant administration of cimetidine and sodium bicarbonate. The time of peak absorption is slightly delayed and the AUC somewhat increased when the oral drug is taken after a meal.
There are no pharmacokinetic data available for 30 mg suppositories. The bioavailability of a 60 mg suppository after single or repeated dosing is approximately 65% of 80 mg of oral tablets given over 24 hours. After rectal administration of 60 mg suppositories, mean domperidone plasma concentrations between 20 and 40 ng/mL are maintained from approximately 0.5 to 5 hours after single- and multiple-dose administration. Following single-dose administration, mean peak plasma levels of 60 mg suppositories are 89% of that of two 10 mg oral tablets, but the mean dose-normalized rectal bioavailability relative to oral tablets is 64%. Following multiple-dose administration, mean peak plasma levels and dose normalized bioavailability of 60 mg suppositories administered every 12 hours are 63% and 66%, respectively, of two 10 mg oral tablets administered every 6 hours.
Distribution: Domperidone is 91-93% bound to plasma proteins. Distribution studies with radiolabelled drug in animals have shown wide tissue distribution, but low brain concentration. Small amounts of drug cross the placenta in rats.
Metabolism: Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in domperidone aromatic hydroxylation.
Excretion: Urinary and fecal excretions amount to 31 and 66% of the oral dose, respectively. The proportion of the drug excreted unchanged is small (10% of fecal excretion and approximately 1% of urinary excretion).
The plasma half-life after a single oral dose is 7-9 hours in healthy subjects, but is prolonged in patients with severe renal insufficiency.
Special Populations: Hepatic impairment: In subjects with moderate hepatic impairment (Pugh score 7 to 9, Child-Pugh rating B), the AUC and C_max of domperidone is 2.9- and 1.5-fold higher, respectively, than in healthy subjects. The unbound fraction is increased by 25%, and the terminal elimination half-life is prolonged from 15 to 23 hours. Subjects with mild hepatic impairment have a somewhat lower systemic exposure than healthy subjects based on C_max and AUC, with no change in protein binding or terminal half-life. Subjects with severe hepatic impairment were not studied (see Contraindications).
Renal impairment: In subjects with severe renal insufficiency (serum creatinine > 6 mg/100 mL, i.e. > 0.6 mmol/L) the half-life of domperidone is increased from 7.4 to 20.8 hours, but plasma drug levels are lower than in subjects with normal renal function. Very little unchanged drug (approximately 1%) is excreted via the kidneys (see Dosage & Administration).
Pediatric patients: Based on limited pharmacokinetic data, domperidone plasma concentrations in preterm neonates were consistent with those reported in adults.
Toxicology: Non-Clinical Information: At a high, maternally toxic dose of 200 mg/kg/day, teratogenic effects (organ abnormalities such as anophthalmia, microphthalmia and displacement of the subclavian artery) were seen in the rat. The clinical significance of these findings is unknown. No teratogenicity was observed in mice and rabbits.
Electrophysiological in vitro and in vivo studies have shown that domperidone, at high concentrations, may prolong the QTc interval.
In juvenile rats, a no observed adverse effect level of 10 mg/kg was observed following 30 days of once daily repeat intraperitoneal dosing. Single intraperitoneal or intravenous doses showed similar LD50 values (mean range 53-76 mg/kg) in both juvenile and adult rats.

The dyspeptic symptom complex that is often associated with delayed gastric emptying, gastro-esophageal reflux and esophagitis: epigastric sense of fullness, early satiety, feeling of abdominal distension, upper abdominal pain; bloating, eructation, flatulence; nausea and vomiting; heartburn with or without regurgitations of gastric contents in the mouth.
Nausea and vomiting of functional, organic, infectious or dietary origin.
For prescription use only: Nausea and vomiting induced by: radiotherapy or drug therapy; dopamine agonists (such as L-dopa and bromocriptine) used in the treatment of Parkinson's disease.

It is recommended to take oral MOTILIUM-M 15-30 minutes before meals. If taken after meals, absorption of the drug is somewhat delayed.
Prescription use: When MOTILIUM-M is used on prescription, the following dosing information applies: Adults and adolescents ≥ 12 years of age and weighing ≥ 35 kg, and children weighing ≥ 35 kg: The dose of MOTILIUM-M should be the lowest effective dose for the individual situation (typically 30 mg/day) and can be increased if necessary to a maximum daily oral dose of 40 mg.
Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. If nausea and vomiting persists for longer than one week, patients should consult their physician. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed. (See Table 2.)

Click on icon to see table/diagram/image

Infants and children < 12 years of age and weighing < 35 kg, and adults and adolescents weighing < 35 kg: The dose of MOTILIUM-M should be the lowest effective dose. The total daily dose is dependent on body weight (see table as follows). Since metabolic functions and the blood-brain barrier are not fully developed in the first months of life, the risk of neurological side effects is higher in young children (see Adverse Reactions). Overdosing may cause nervous system disorders in children (see Overdosage). The dose should be determined accurately based on body weight and not exceed the recommended maximum individual and daily dose in neonates, infants, toddlers and children.
Usually, the maximum treatment duration should not exceed one week for the treatment of acute nausea and vomiting. For other indications, the initial duration of treatment is up to four weeks. If treatment exceeds four weeks, patients should be reevaluated and the need for continued treatment reassessed. Film-coated tablets is unsuitable for use in children, adults and adolescents weighing less than 35 kg.
Renal impairment: Since the elimination half-life of domperidone is prolonged in severe renal impairment (serum creatinine > 6 mg/100 mL, i.e. > 0.6 mmol/L), the dosing frequency of MOTILIUM-M should be reduced to once or twice daily, depending on the severity of the impairment, and the dose may need to be reduced. Patients with severe renal impairment should be reviewed regularly (see Pharmacology: Pharmacokinetics under Actions).
Hepatic impairment: MOTILIUM-M is contraindicated for patients with moderate (Child-Pugh 7 to 9) or severe (Child-Pugh >9) hepatic impairment (see Contraindications). Dose adjustment is not required for patients with mild (Child-Pugh 5 to 6) hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).

Symptoms and signs: Overdose has been reported primarily in infants and children. Symptoms of overdose may include agitation, altered consciousness, convulsion, disorientation, somnolence and extrapyramidal reactions.
Treatment: There is no specific antidote to domperidone, but in the event of a large overdose, gastric lavage within one hour of ingestion as well as the administration of activated charcoal may be useful. Close medical supervision and supportive therapy is recommended. Anticholinergic or anti-Parkinson drugs may be helpful in controlling the extrapyramidal reactions.

MOTILIUM-M is contraindicated in the following situations: Known hypersensitivity to domperidone or any of the excipients; Prolactin-releasing pituitary tumor (prolactinoma).
Co-administration with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation such as, clarithromycin, erythromycin, itraconazole, oral ketoconazole, posaconazole, ritonavir, saquinavir, telithromycin, telaprevir and voriconazole (see Precautions, and Interactions).
Whenever stimulation of gastric motility might be dangerous, e.g., in the presence of gastro-intestinal hemorrhage, mechanical obstruction or perforation.
In patients with moderate or severe hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).

Cardiac effects: Epidemiological studies have shown domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death (see Adverse Reactions). Those studies suggest this increased risk may be higher in patients older than 60 years of age or in patients taking oral doses greater than 30 mg per day. Therefore, MOTILIUM-M should be used with caution in older patients.
Treatment with MOTILIUM-M should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patient should promptly consult their physician.
Drug interaction potential: The main metabolic pathway of domperidone is through CYP3A4. In vitro and human data show that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone.
Co-administration of domperidone with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation is contraindicated (see Contraindications).
Caution should be exercised when domperidone is co-administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation such as indinavir and patients should be monitored closely for signs or symptoms of adverse reactions (see Adverse Reactions).
Caution should be exercised when domperidone is co-administered with drugs which have been shown to cause QT interval prolongation and patients should be monitored closely for signs or symptoms of cardiovascular adverse reactions (see Adverse Reactions). Examples include: anti-arrhythmics class IA (e.g., disopyramide, quinidine); anti-arrhythmics class III (e.g., amiodarone, dofetilide, dronedarone, ibutilide, sotalol); certain antipsychotics (e.g., haloperidol, pimozide, sertindole); certain antidepressants (e.g., citalopram, escitalopram); certain antibiotics (e.g., levofloxacin, moxifloxacin); certain antifungal agents (e.g., pentamidine); certain antimalarial agents (e.g., halofantrine); certain gastro-intestinal drugs (e.g., dolasetron); certain drugs used in cancer (e.g., toremifene, vandetanib); certain other drugs (e.g., bepridil, methadone).
The previously mentioned list is representative and not exhaustive. Refer to relevant lists appropriate for the country.
Antacids or antisecretory agents should not be taken simultaneously with oral formulations of MOTILIUM-M as they lower the oral bioavailability of domperidone. When used concomitantly, MOTILIUM-M should be taken before meals and antacids or antisecretory agents after meals.
Excipients of MOTILIUM-M (domperidone maleate): The film-coated tablets contain lactose and may be unsuitable for patients with lactose intolerance, galactosemia or glucose/galactose malabsorption.
Effects on Ability to Drive and Use Machines: Dizziness and somnolence have been observed following use of domperidone (see Adverse Reactions). Therefore, patients should be advised not to drive or use machinery or engage in other activities requiring mental alertness and coordination until they have established how MOTILIUM-M affects them.

Pregnancy: There are limited post-marketing data on the use of domperidone in pregnant women. A study in rats has shown reproductive toxicity at a high, maternally toxic dose. The potential risk for humans is unknown. Therefore, MOTILIUM-M should only be used during pregnancy when justified by the anticipated therapeutic benefit.
Breast-feeding: The amount of domperidone that could be ingested by an infant through breast milk is low. The maximal relative infant dose (%) is estimated to be about 0.1% of the maternal weight-adjusted dosage. It is not known whether this is harmful to the newborn. Therefore, breast-feeding is not recommended for women who are taking MOTILIUM-M.

Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of domperidone based on the comprehensive assessment of the available adverse event information. A causal relationship with domperidone cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinical Trial Data: The safety of MOTILIUM-M was evaluated in 1221 patients with gastroparesis, dyspepsia, gastro-esophageal reflux disorder (GERD), or other related conditions in 45 clinical trials included in the safety database. All patients were ≥ 15 years old and received at least one dose of oral domperidone base. Slightly fewer than one-half (553/1221) of patients were diabetic. The median total daily dose was 80 mg (range 10 to 160 mg), with 230 patients receiving a dose greater than 80 mg. Median duration of exposure was 56 days (range 1 to 2248 days).
ARs reported by ≥ 1% of patients treated with domperidone in these 45 clinical trials are shown in Table 3. (See Table 3.)

Click on icon to see table/diagram/image

ARs that occurred in < 1% of Domperidone-treated patients in the 45 clinical trials (n=1221) are listed as follows in Table 4. (See Table 4.)

Click on icon to see table/diagram/image

The following adverse reaction has been reported with over-the-counter use: dry mouth.
Postmarketing: In addition to the ARs reported during clinical studies and listed previously, the following ARs have been reported during postmarketing experience (Table 5). In the table, the frequencies are provided according to the following convention: Very common ≥ 1/10; Common ≥ 1/100, and < 1/10; Uncommon ≥ 1/1000 and < 1/100; Rare ≥ 1/10000 and < 1/1000; Very rare < 1/10000, including isolated reports.
In Table 6, ARs are presented by frequency category based on spontaneous reporting rates. (See Table 5.)

Click on icon to see table/diagram/image

Pediatric population: In postmarketing experience, there were no differences in the safety profile of adults and children, with the exception of extrapyramidal disorder which occurred primarily in neonates and infants (up to one year of age) and other central nervous system-related effects of convulsion and agitation which were reported primarily in infants and children.

The main metabolic pathway of domperidone is through CYP3A4. In vitro and human data show that the concomitant use of drugs that significantly inhibit this enzyme may result in increased plasma levels of domperidone.
When domperidone was co-administered with potent CYP3A4 inhibitors which have been shown to cause QT interval prolongation, clinically relevant changes in QT intervals were observed. Therefore, co-administration of domperidone with certain drugs is contraindicated (see Contraindications).
Caution should be exercised when domperidone is co-administered with potent CYP3A4 inhibitors which have not been shown to cause QT interval prolongation or drugs which have been shown to cause QT interval prolongation (see Precautions).
Concomitant administration of anticholinergic drugs (e.g., dextromethorphan, diphenhydramine) may antagonize the anti-dyspeptic effect of MOTILIUM-M.
Theoretically, since MOTILIUM-M has gastro-kinetic effects, it could influence the absorption of concomitantly orally administered drugs, particularly those with sustained-release or enteric-coated formulations. However, in patients already stabilized on digoxin or paracetamol, concomitant administration of domperidone did not influence the blood levels of these drugs.
MOTILIUM-M may also be given with: neuroleptics, the action of which it does not potentiate, dopaminergic agonists (bromocriptine, L-dopa), whose unwanted peripheral effects such as digestive disorders, nausea and vomiting it suppresses without counteracting their central properties.

Incompatibilities: None known.
Instructions for Use and Handling: Not applicable.

Store below 30°C.

GIT Regulators, Antiflatulents & Anti-Inflammatories / Antiemetics

A03FA03 - domperidone ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.

POM

FC tab 10 mg (off-white, round, with "
Click on icon to see table/diagram/image
" printed on one side and the name "Janssen" appears on the other) x 10 x 10's, 50 x 10's.